This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Becton Dickinson Management

Management criteria checks 2/4

Becton Dickinson's CEO is Tom Polen, appointed in Apr 2017, he has a tenure of 6.17 years. His total yearly compensation is $16.71M , comprised of 7.6% salary and 92.4% bonuses, including company stock and options. He directly owns 0.011% of the company’s shares, worth $7.69M. The average tenure of the management team and the board of directors is 1.6 years and 6.6 years respectively.

Key information

Tom Polen

Chief executive officer

US$16.7m

Total compensation

CEO salary percentage	7.6%
CEO tenure	6.2yrs
CEO ownership	0.01%
Management average tenure	1.6yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tom Polen's remuneration changed compared to Becton Dickinson's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$1b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$245m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m
Jun 30 2018	n/a	n/a	US$621m
Mar 31 2018	n/a	n/a	-US$99m
Dec 31 2017	n/a	n/a	US$294m
Sep 30 2017	US$4m	US$761k	US$1b
Jun 30 2017	n/a	n/a	US$759m
Mar 31 2017	n/a	n/a	US$1b
Dec 31 2016	n/a	n/a	US$1b
Sep 30 2016	US$3m	US$651k	US$976m

Compensation vs Market: Tom's total compensation ($USD16.71M) is above average for companies of similar size in the US market ($USD12.47M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

CEO

Tom Polen (50 yo)

6.2yrs

Tenure

US$16,711,230

Compensation

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Polen	President	6.2yrs	US$16.71m	0.011% $ 7.7m
Christopher DelOrefice	Executive VP & CFO	1.8yrs	US$5.77m	0.00056% $ 394.6k
Shana Neal	Executive VP & Chief People Officer	1.2yrs	US$3.34m	0.0060% $ 4.2m
David Hickey	Executive VP & President of Life Sciences Segment	no data	US$3.26m	0.0031% $ 2.2m
Thomas Spoerel	Senior VP	3.7yrs	no data	0.00069% $ 486.2k
Elizabeth McCombs	Executive VP & Chief Technology Officer	2.2yrs	no data	no data
Joseph Smith	Senior VP	1.6yrs	no data	no data
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	1.4yrs	no data	no data
Francesca DeMartino	Senior VP & Head of Investor Relations	1.6yrs	no data	no data
Michelle Quinn	Executive VP & General Counsel	less than a year	no data	0.0011% $ 810.4k
Ami Simunovich	Executive VP	less than a year	no data	no data
Antoine Ezell	Executive VP	3.4yrs	no data	0.0025% $ 1.8m

1.6yrs

Average Tenure

53yo

Average Age

Experienced Management: BDXB's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Polen	President	3.4yrs	US$16.71m	0.011% $ 7.7m
Joseph Smith	Senior VP	1.6yrs	no data	no data
John DeFord	Co-Chair of Scientific Advisory Board	2.1yrs	no data	no data
Marshall Larsen	Independent Director	15.8yrs	US$383.58k	0.010% $ 7.2m
Robert Eckert	Independent Director	6.8yrs	US$318.58k	0.0025% $ 1.7m
Timothy Ring	Independent Director	6.4yrs	US$323.58k	0.029% $ 20.2m
Jeffrey Henderson	Independent Director	4.8yrs	US$318.58k	0.0016% $ 1.2m
Christopher Ian Jones	Independent Director	12.9yrs	US$343.58k	0.010% $ 7.2m
Bertram Scott	Lead Independent Director	20.8yrs	US$343.58k	0.012% $ 8.4m
Catherine Burzik	Independent Director	10.4yrs	US$348.58k	0.0047% $ 3.3m
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	16.6yrs	US$347.58k	0.0079% $ 5.5m
Carrie Byington	Independent Director	1.7yrs	US$323.58k	0.00068% $ 479.2k

6.6yrs

Average Tenure

65yo

Average Age

Experienced Board: BDXB's board of directors are considered experienced (6.6 years average tenure).

This company listing is no longer active

Becton Dickinson Management

Management criteria checks 2/4

Key information

Recent management updates

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Announces Management Changes

Recent updates

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD Announces Voluntary Recall on Intraosseous Products

Becton, Dickinson and Company Appoints Simon Campion as Executive Vice President and President of the Medical Segment, Effective July 1, 2022

Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a definitive agreement to acquire Parata Systems, LLC from Frazier Healthcare Partners for $1.5 billion.

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2022

New Becton, Dickinson and Company Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Becton, Dickinson and Company to Report Q2, 2022 Results on May 05, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Announces Retirement of Alberto Mas as Executive Vice President and President of the Medical Segment, Effective September 30, 2022

Becton, Dickinson and Company Appoints William Bill Brown to Board of Directors

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A.

Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the BD Kiestra™ Identifa System

BD Announces New Distribution and Retail Partners for Bd Veritor At-Home Covid-19 Test

Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc.

BD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core Labs

Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd.

Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc.

Becton, Dickinson and Company Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results

BD (Becton, Dickinson and Company) Announces the Launch of A New Benchtop Cell Analyzer

Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc.

BD Announces Expanded 510(k) Clearance for At-Home System for Ascites

Becton, Dickinson and Company Launches Urine Culture Application

Becton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC.

Becton, Dickinson and Company Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets

BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2021

BD Announces FDA 510(k) Submission for BD Alaris™ System

BD Announces Collaboration with ImageMover for Rapid Antigen Test Reporting

Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc.

BD and Scanwell Health Announces Collaboration for At-Home Rapid Test for COVID-19

BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021

Becton, Dickinson and Company Announces New Clinical Data Found Robust Evidence Using A Vascular Care Solution

Becton, Dickinson and Company Announces Board Changes